OVERVIEW

11th International Viral Hepatitis Elimination Meeting (IVHEM) is organized by Academic Medical Education (AME), Coalition for Global Hepatitis Elimination (CGHE) and will be held from Sep 12 - 13, 2025 at COEX Magok Le West, Gangseo-gu, Seoul, South Korea.

Description:
The International Viral Hepatitis Elimination Meeting (IVHEM) is a global forum for the exchange of practical experiences for translating diagnostic and therapy advances of viral hepatitis into broad applications that accelerate progress towards the elimination of viral hepatitis as a public health threat by 2030.

Hepatitis B and C affect more than 354 million people globally and can lead to liver disease and mortality from liver failure and hepatocellular carcinoma. More than 296 million people (3.7% of the world’s population) live with HBV, and over 820,000 deaths are attributable annually. An estimated 58 million people (globally, 0.73%) live with the hepatitis C virus (HCV), resulting in nearly 290,000 deaths annually.

Key issues to be addressed are how to translate research outcomes into public health policy and practice to meet the 2030 elimination targets. During this two-day meeting, experts in viral hepatitis from around the globe will examine current evidence on how to implement programs that improve the prevention of viral hepatitis and increase the number of people accessing testing and treatment.

The program includes practical examples of innovative intervention studies, country elimination programs, and novel funding mechanisms for testing and treatment.

Meeting Objectives:
This meeting aims to:

Provide a forum for knowledge exchange and discussion of practical experiences related to the clinical management of viral hepatitis;
Provide a toolbox for the practical application of research & development for evidence-based policymaking; and
Facilitate cross-disciplinary discussion on barriers and challenges preventing the elimination of viral hepatitis.

Learning Objectives:
After participating in this activity, participants will be able to:

Identify innovative strategies for hepatitis b and hepatitis C testing and linkage to care and how these can be applied to their program and clinical activities;
Recognize the needs from a public health perspective and respond to these needs by reshaping their policymaking approaches;
Further develop new or strengthen already existing foundations for political commitment, national planning, and program improvements; and
Translate the latest research and technologies into clinical policy and practice for delivering an adequate continuum of viral hepatitis services.